

Richard Moss

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8909818/publications.pdf>

Version: 2024-02-01

149
papers

15,741
citations

23500

58
h-index

16605

123
g-index

153
all docs

153
docs citations

153
times ranked

9915
citing authors

#	ARTICLE	IF	CITATIONS
1	A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation. <i>New England Journal of Medicine</i> , 2011, 365, 1663-1672.	13.9	1,920
2	Lumacaftor (ivacaftor) in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. <i>New England Journal of Medicine</i> , 2015, 373, 220-231.	13.9	1,308
3	Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation. <i>New England Journal of Medicine</i> , 2010, 363, 1991-2003.	13.9	741
4	Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. <i>Clinical and Experimental Allergy</i> , 2013, 43, 850-873.	1.4	666
5	Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis: State of the Art: Cystic Fibrosis Foundation Consensus Conference. <i>Clinical Infectious Diseases</i> , 2003, 37, S225-S264.	2.9	658
6	Late Pulmonary Sequelae of Bronchopulmonary Dysplasia. <i>New England Journal of Medicine</i> , 1990, 323, 1793-1799.	13.9	515
7	Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. <i>Thorax</i> , 2012, 67, 12-18.	2.7	466
8	Fungi and allergic lower respiratory tract diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 280-291.	1.5	398
9	A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2014, 2, 527-538.	5.2	372
10	Repeated Adeno-Associated Virus Serotype 2 Aerosol-Mediated Cystic Fibrosis Transmembrane Regulator Gene Transfer to the Lungs of Patients With Cystic Fibrosis. <i>Chest</i> , 2004, 125, 509-521.	0.4	351
11	Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2014, 2, 539-547.	5.2	301
12	Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 841-849.	2.5	300
13	A Phase II, Double-Blind, Randomized, Placebo-Controlled Clinical Trial of tgAAVCF Using Maxillary Sinus Delivery in Patients with Cystic Fibrosis with Antrostomies. <i>Human Gene Therapy</i> , 2002, 13, 1349-1359.	1.4	239
14	Repeated Aerosolized AAV-CFTR for Treatment of Cystic Fibrosis: A Randomized Placebo-Controlled Phase 2B Trial. <i>Human Gene Therapy</i> , 2007, 18, 726-732.	1.4	239
15	High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 4628-4633.	3.3	235
16	Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 107-118.	5.2	235
17	Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. <i>Lancet</i> , 1998, 351, 1702-1703.	6.3	220
18	A Phase I Study of Aerosolized Administration of tgAAVCF to Cystic Fibrosis Subjects with Mild Lung Disease. <i>Human Gene Therapy</i> , 2001, 12, 1907-1916.	1.4	219

#	ARTICLE	IF	CITATIONS
19	Comparative Efficacy and Safety of 4 Randomized Regimens to Treat Early <i>Pseudomonas aeruginosa</i> Infection in Children With Cystic Fibrosis. <i>JAMA Pediatrics</i> , 2011, 165, 847.	3.6	199
20	Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2015, 3, 524-533.	5.2	197
21	Safety and Biological Efficacy of an Adeno-Associated Virus Vector-Cystic Fibrosis Transmembrane Regulator (AAV-CFTR) in the Cystic Fibrosis Maxillary Sinus. <i>Laryngoscope</i> , 1999, 109, 266-274.	1.1	193
22	Seasonal asthma in northern California: Allergic causes and efficacy of immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 1986, 78, 590-600.	1.5	182
23	Long-term Benefits of Inhaled Tobramycin in Adolescent Patients With Cystic Fibrosis. <i>Chest</i> , 2002, 121, 55-63.	0.4	158
24	Cow's milk allergy in breast-fed infants: The role of allergen and maternal secretory IgA antibody. <i>Journal of Allergy and Clinical Immunology</i> , 1986, 77, 341-347.	1.5	153
25	Bone acquisition and loss in children and adults with cystic fibrosis: A longitudinal study. <i>Journal of Pediatrics</i> , 1998, 133, 18-27.	0.9	148
26	Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. <i>Journal of Pediatrics</i> , 1988, 112, 547-554.	0.9	143
27	Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis. <i>Chest</i> , 1999, 115, 364-370.	0.4	143
28	Osteopenia in adults with cystic fibrosis. <i>American Journal of Medicine</i> , 1994, 96, 27-34.	0.6	141
29	Sputum Cathelicidin, Urokinase Plasminogen Activation System Components, and Cytokines Discriminate Cystic Fibrosis, COPD, and Asthma Inflammation. <i>Chest</i> , 2005, 128, 2316-2326.	0.4	140
30	Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 4335-4339.	3.3	126
31	Comparison of a β -lactam alone versus β -lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. <i>Journal of Pediatrics</i> , 1999, 134, 413-421.	0.9	124
32	Grass pollen immunotherapy: A single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 1984, 73, 283-290.	1.5	112
33	Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. <i>Clinical and Experimental Immunology</i> , 2000, 120, 518-525.	1.1	107
34	Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2013, 12, 241-248.	0.3	102
35	Dornase Alfa Reduces Air Trapping in Children With Mild Cystic Fibrosis Lung Disease. <i>Chest</i> , 2005, 128, 2327-2335.	0.4	96
36	A Phase I/II Study of tgAAV-CF for the Treatment of Chronic Sinusitis in Patients with Cystic Fibrosis. Stanford University, Stanford, California. <i>Human Gene Therapy</i> , 1998, 9, 889-909.	1.4	95

#	ARTICLE	IF	CITATIONS
37	A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis. <i>Human Molecular Genetics</i> , 1998, 7, 729-735.	1.4	92
38	Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5779-5783.	3.3	90
39	Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. <i>Journal of Cystic Fibrosis</i> , 2015, 14, 219-227.	0.3	90
40	Pulmonary Sequelae of Bronchopulmonary Dysplasia Survivors. <i>American Journal of Roentgenology</i> , 2000, 174, 1323-1326.	1.0	88
41	Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2007, 42, 610-623.	1.0	88
42	Long term effects of denufosal tetrasodium in patients with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2012, 11, 539-549.	0.3	85
43	Administration of Aerosolized Antibiotics in Cystic Fibrosis Patients. <i>Chest</i> , 2001, 120, 107S-113S.	0.4	84
44	Sinus disease in patients with severe cystic fibrosis: relation to pulmonary exacerbation. <i>Lancet</i> , The, 1990, 335, 1077-1078.	6.3	82
45	Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis. <i>European Respiratory Journal</i> , 2014, 43, 1487-1500.	3.1	82
46	Earth Mover's Distance (EMD): A True Metric for Comparing Biomarker Expression Levels in Cell Populations. <i>PLoS ONE</i> , 2016, 11, e0151859.	1.1	82
47	Allergy to semisynthetic penicillins in cystic fibrosis. <i>Journal of Pediatrics</i> , 1984, 104, 460-466.	0.9	81
48	No Detectable Improvements in Cystic Fibrosis Transmembrane Conductance Regulator by Nasal Aminoglycosides in Patients with Cystic Fibrosis with Stop Mutations. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2007, 37, 57-66.	1.4	81
49	Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). <i>Clinical and Experimental Immunology</i> , 1996, 106, 374-388.	1.1	80
50	Composite Spirometric-Computed Tomography Outcome Measure in Early Cystic Fibrosis Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 588-593.	2.5	78
51	Pathophysiology and immunology of allergic bronchopulmonary aspergillosis. <i>Medical Mycology</i> , 2005, 43, 203-206.	0.3	78
52	Inhibition of <i>Aspergillus fumigatus</i> and Its Biofilm by <i>Pseudomonas aeruginosa</i> Is Dependent on the Source, Phenotype and Growth Conditions of the Bacterium. <i>PLoS ONE</i> , 2015, 10, e0134692.	1.1	77
53	Quantitative air-trapping analysis in children with mild cystic fibrosis lung disease. <i>Pediatric Pulmonology</i> , 2004, 38, 396-405.	1.0	73
54	Spirometer-triggered high-resolution computed tomography and pulmonary function measurements during an acute exacerbation in patients with cystic fibrosis. <i>Journal of Pediatrics</i> , 2001, 138, 553-559.	0.9	71

#	ARTICLE	IF	CITATIONS
55	Allergic bronchopulmonary aspergillosis and <i>Aspergillus</i> infection in cystic fibrosis. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 598-603.	1.2	71
56	Denofosol Tetrasodium in Patients with Cystic Fibrosis and Normal to Mildly Impaired Lung Function. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 627-634.	2.5	71
57	Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1996, 153, 1914-1917.	2.5	67
58	Suppression of the late cutaneous response by immunotherapy ¹ . <i>Journal of Allergy and Clinical Immunology</i> , 1989, 83, 101-109.	1.5	61
59	Safety, Tolerability, and Efficacy of High-Frequency Chest Wall Oscillation in Pediatric Patients With Cerebral Palsy and Neuromuscular Diseases: An Exploratory Randomized Controlled Trial. <i>Journal of Child Neurology</i> , 2010, 25, 815-821.	0.7	59
60	Constipation and meconium ileus equivalent in patients with cystic fibrosis. <i>Pediatrics</i> , 1986, 78, 473-9.	1.0	58
61	Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study of Aerosolized Interferon Gamma-1b in Patients With Mild to Moderate Cystic Fibrosis Lung Disease. <i>Pediatric Pulmonology</i> , 2005, 39, 209-218.	1.0	55
62	Allergic Bronchopulmonary Aspergillosis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2016, 2, 17.	1.5	55
63	Sensitization to aztreonam and cross-reactivity with other beta-lactam antibiotics in high-risk patients with cystic fibrosis. <i>Journal of Allergy and Clinical Immunology</i> , 1991, 87, 78-88.	1.5	54
64	Deficiency of IgG4 in children: Association of isolated IgG4 deficiency with recurrent respiratory tract infection. <i>Journal of Pediatrics</i> , 1992, 120, 16-21.	0.9	52
65	Immune complexes and humoral response to <i>Pseudomonas aeruginosa</i> in cystic fibrosis. <i>The American Review of Respiratory Disease</i> , 1980, 121, 23-9.	2.9	52
66	Baseline Characteristics and Factors Associated With Nutritional and Pulmonary Status at Enrollment in the Cystic Fibrosis EPIC Observational Cohort. <i>Pediatric Pulmonology</i> , 2010, 45, 934-944.	1.0	51
67	Altered Antibody Isotype in Cystic Fibrosis. Possible Role in Opsonic Deficiency. <i>Pediatric Research</i> , 1986, 20, 453-459.	1.1	49
68	A Little CFTR Goes a Long Way: CFTR-Dependent Sweat Secretion from G551D and R117H-5T Cystic Fibrosis Subjects Taking Ivacaftor. <i>PLoS ONE</i> , 2014, 9, e88564.	1.1	49
69	Molecular epidemiology of <i>Aspergillus</i> collected from cystic fibrosis patients. <i>Journal of Cystic Fibrosis</i> , 2015, 14, 474-481.	0.3	48
70	The basophil surface marker CD203c identifies <i>Aspergillus</i> species sensitization in patients with cystic fibrosis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 436-443.e9.	1.5	47
71	Specific antibodies to recombinant allergens of <i>Aspergillus fumigatus</i> in cystic fibrosis patients with ABPA. <i>Clinical and Molecular Allergy</i> , 2006, 4, 11.	0.8	45
72	Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation. <i>PLoS ONE</i> , 2013, 8, e66955.	1.1	44

#	ARTICLE	IF	CITATIONS
73	Isotypic and antigenic restriction of the blocking antibody response to ryegrass pollen: Correlation of rye group I antigen-specific IgG1 with clinical response. <i>Journal of Allergy and Clinical Immunology</i> , 1987, 79, 387-398.	1.5	43
74	<i>Pseudomonas</i> hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis. <i>Pediatric Pulmonology</i> , 1990, 9, 7-18.	1.0	42
75	Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis. <i>Current Opinion in Pediatrics</i> , 2018, 30, 372-377.	1.0	42
76	125I-Clq-binding and specific antibodies as indicators of pulmonary disease activity in cystic fibrosis. <i>Journal of Pediatrics</i> , 1981, 99, 215-222.	0.9	41
77	Diagnostic Testing by CFTR Gene Mutation Analysis in a Large Group of Hispanics. <i>Journal of Molecular Diagnostics</i> , 2005, 7, 289-299.	1.2	40
78	Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by aspergillus allergens. <i>Journal of Cystic Fibrosis</i> , 2012, 11, 502-510.	0.3	40
79	Pitfalls of Drug Development: Lessons Learned from Trials of Denufosal in Cystic Fibrosis. <i>Journal of Pediatrics</i> , 2013, 162, 676-680.	0.9	40
80	Safety and Preliminary Clinical Activity of a Novel Pancreatic Enzyme Preparation in Pancreatic Insufficient Cystic Fibrosis Patients. <i>Pancreas</i> , 2006, 32, 258-263.	0.5	39
81	Sputum Tobramycin Concentrations in Cystic Fibrosis Patients with Repeated Administration of Inhaled Tobramycin. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2013, 26, 69-75.	0.7	39
82	Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis. <i>European Respiratory Journal</i> , 2016, 47, 177-185.	3.1	39
83	The myriad challenges of respiratory fungal infection in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2018, 53, S75-S85.	1.0	39
84	Nonopsonic antibodies in cystic fibrosis. <i>Pseudomonas aeruginosa</i> lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.. <i>Journal of Clinical Investigation</i> , 1989, 84, 1794-1804.	3.9	37
85	Socioeconomic Status and the Likelihood of Antibiotic Treatment for Signs and Symptoms of Pulmonary Exacerbation in Children with Cystic Fibrosis. <i>Journal of Pediatrics</i> , 2011, 159, 819-824.e1.	0.9	36
86	Anti-arthropod saliva antibodies among residents of a community at high risk for Lyme disease in California.. <i>American Journal of Tropical Medicine and Hygiene</i> , 1999, 61, 850-859.	0.6	36
87	Altered Antibody Isotype in Cystic Fibrosis: Impaired Natural Antibody Response to Polysaccharide Antigens. <i>Pediatric Research</i> , 1987, 22, 708-713.	1.1	33
88	Two novel mutations in a cystic fibrosis patient of Chinese origin. <i>Human Genetics</i> , 1999, 104, 511-515.	1.8	33
89	Fungi in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 207-216.	0.8	32
90	Comprehensive Mutation Screening in a Cystic Fibrosis Center. <i>Pediatrics</i> , 2001, 107, 280-286.	1.0	28

#	ARTICLE	IF	CITATIONS
91	Cystic fibrosis HRCT scores correlate strongly with pseudomonas infection. <i>Pediatric Pulmonology</i> , 2009, 44, 1107-1117.	1.0	27
92	Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials in patients with anrostomies. <i>Journal of Gene Medicine</i> , 1999, 1, 13-21.	1.4	27
93	Hypergammaglobulinemia in Cystic Fibrosis. <i>Chest</i> , 1987, 91, 522-526.	0.4	26
94	Fully Automated System for Three-Dimensional Bronchial Morphology Analysis Using Volumetric Multidetector Computed Tomography of the Chest. <i>Journal of Digital Imaging</i> , 2006, 19, 132-139.	1.6	26
95	The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis. <i>Annals of the New York Academy of Sciences</i> , 2012, 1272, 49-57.	1.8	26
96	Underestimation of specific immunoglobulin E by microtiter plate enzyme-linked immunosorbent assays. <i>Journal of Allergy and Clinical Immunology</i> , 1985, 76, 172-176.	1.5	25
97	Alternative Pharmacotherapies for Steroid-Dependent Asthma. <i>Chest</i> , 1995, 107, 817-825.	0.4	24
98	Stevens et al. (2003;â€%37[Suppl 3]:S225â€%64). <i>Clinical Infectious Diseases</i> , 2004, 38, 158-158.	2.9	24
99	Interobserver Variance in Clinical Scoring for Cystic Fibrosis. <i>Chest</i> , 1987, 91, 878-882.	0.4	22
100	Reproducibility of skin prick testing with allergen extracts from different manufacturers. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1988, 43, 458-463.	2.7	21
101	IgE antibodies in tick bite-induced anaphylaxis. <i>Journal of Allergy and Clinical Immunology</i> , 1991, 88, 968-970.	1.5	20
102	Advances against Aspergillosis. <i>Clinical Infectious Diseases</i> , 2003, 37, S155-S156.	2.9	20
103	Lymphocytes in cystic fibrosis lung disease: a tale of two immunities. <i>Clinical and Experimental Immunology</i> , 2004, 135, 358-360.	1.1	20
104	Critique of trials in allergic bronchopulmonary aspergillosis and fungal allergy. <i>Medical Mycology</i> , 2006, 44, S269-S272.	0.3	20
105	Resistin is elevated in cystic fibrosis sputum and correlates negatively with lung function. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 64-70.	0.3	20
106	Highlights of a workshop to discuss targeting inflammation in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2009, 8, 1-8.	0.3	18
107	Small Colony Variants of <i>Pseudomonas aeruginosa</i> Display Heterogeneity in Inhibiting <i>Aspergillus fumigatus</i> Biofilm. <i>Mycopathologia</i> , 2018, 183, 263-272.	1.3	18
108	Treating allergic bronchopulmonary aspergillosis: the way forward. <i>European Respiratory Journal</i> , 2016, 47, 385-387.	3.1	17

#	ARTICLE	IF	CITATIONS
109	Supraventricular Tachycardia in Patients with Cystic Fibrosis. <i>Chest</i> , 1986, 90, 239-242.	0.4	16
110	Activation of Eosinophils in the Airways of Lung Transplantation Patients. <i>Chest</i> , 1997, 112, 1180-1183.	0.4	16
111	Effect of Media Modified To Mimic Cystic Fibrosis Sputum on the Susceptibility of <i>Aspergillus fumigatus</i> , and the Frequency of Resistance at One Center. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2180-2184.	1.4	16
112	Mucus plugging, air trapping, and bronchiectasis are important outcome measures in assessing progressive childhood cystic fibrosis lung disease. <i>Pediatric Pulmonology</i> , 2020, 55, 929-938.	1.0	16
113	Biomarkers for the Diagnosis of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis: A Systematic Review and Meta-Analysis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1909-1930.e4.	2.0	15
114	Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation. <i>Journal of Cystic Fibrosis</i> , 2018, 17, 503-510.	0.3	14
115	Are Cystic Fibrosis <i>Aspergillus fumigatus</i> Isolates Different? Intermicrobial Interactions with <i>Pseudomonas</i> . <i>Mycopathologia</i> , 2017, 182, 315-318.	1.3	13
116	Infection, Inflammation, and the Downward Spiral of Cystic Fibrosis Lung Disease. <i>Journal of Pediatrics</i> , 2009, 154, 162-163.	0.9	10
117	Clinician variability in the diagnosis and treatment of aspergillus fumigatus-related conditions in cystic fibrosis: An international survey. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 136-142.	0.3	10
118	Manifestations of pulmonary aspergillosis in pediatrics. <i>Current Opinion in Pediatrics</i> , 2020, 32, 389-394.	1.0	10
119	Recent advances in cystic fibrosis. <i>Current Opinion in Pediatrics</i> , 2015, 27, 317-324.	1.0	8
120	Effect of total lymphoid irradiation on IgE antibody responses in rheumatoid arthritis and systemic lupus erythematosus. <i>Journal of Allergy and Clinical Immunology</i> , 1987, 80, 798-802.	1.5	7
121	Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults. <i>Scientific Reports</i> , 2018, 8, 16233.	1.6	7
122	Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations. <i>Pulmonary Therapy</i> , 2020, 6, 303-313.	1.1	7
123	The magnitude of ivacaftor effects on fluid secretion via R117H-CFTR channels: Human in vivo measurements. <i>PLoS ONE</i> , 2017, 12, e0175486.	1.1	7
124	Current treatment options for invasive aspergillosis. <i>Drugs of Today</i> , 2013, 49, 213.	0.7	6
125	Basophil activation test determination of CD63 combined with CD203c is not superior to CD203c alone in identifying allergic bronchopulmonary aspergillosis in cystic fibrosis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1195-1196.	1.5	6
126	124 Grass pollen immunotherapy, clinical and immunologic effects in a double-blind placebo-controlled study. <i>Journal of Allergy and Clinical Immunology</i> , 1983, 71, 119.	1.5	5

#	ARTICLE	IF	CITATIONS
127	Novel cystic fibrosis mutation L1093P: Functional analysis and possible Native American origin. , 2000, 15, 208-208.		5
128	Diagnosing allergic bronchopulmonary aspergillosis/mycosis: Return to lost horizons. Journal of Allergy and Clinical Immunology, 2021, 147, 1212-1214.	1.5	5
129	Management of allergic aspergillosis. Current Fungal Infection Reports, 2008, 2, 87-93.	0.9	4
130	Mucosal humoral immunity in cystic fibrosis - a tangled web of failed proteostasis, infection and adaptive immunity. EBioMedicine, 2020, 60, 103035.	2.7	4
131	Immunoglobulin E antibodies in young children with possible allergic symptoms. Journal of Pediatrics, 1987, 110, 738-740.	0.9	3
132	Management of allergic aspergillosis. Current Allergy and Asthma Reports, 2008, 8, 433-439.	2.4	3
133	Novel contributions to the Asian CFTR mutation spectrum: Genotype and phenotype in Thai patients with cystic fibrosis. American Journal of Medical Genetics, Part A, 2005, 133A, 103-105.	0.7	2
134	Early Aspergillosis in Cystic Fibrosis and Air Trapping: Guilt by Association?. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 644-645.	2.5	2
135	37 Infantile allergy and milk-specific antibodies in breast milk. Journal of Allergy and Clinical Immunology, 1983, 71, 98.	1.5	1
136	493 Suppression of the Late Cutaneous Response (LCR) by immunotherapy (IT). Journal of Allergy and Clinical Immunology, 1988, 81, 291.	1.5	1
137	A PILOT STUDY OF POLYSOMNOGRAPHY TO EVALUATE EFFECTIVENESS OF AIRWAY CLEARANCE THERAPIES IN PEDIATRIC PATIENTS WITH CEREBRAL PALSY AND NEUROMUSCULAR DISORDERS. Chest, 2007, 132, 609A.	0.4	1
138	Basophil Activation Is a Reliable Biomarker Of Allergic Bronchopulmonary Aspergillosis (ABPA) In CF: One Year Results Of a Longitudinal Cohort Study. Journal of Allergy and Clinical Immunology, 2014, 133, AB58.	1.5	1
139	Modulatory Effects of Aspergillus Colonization and Abpa on Blood and Sputum Granulocytes in CF. Journal of Allergy and Clinical Immunology, 2016, 137, AB29.	1.5	1
140	Susceptibility of Candida albicans from Cystic Fibrosis Patients. Mycopathologia, 2017, 182, 863-867.	1.3	1
141	P255â€¦Rate of lung function decline in patients with cystic fibrosis (cf) having a residual function gene mutation. , 2017, , .		1
142	Spirometer-Triggered High Resolution Computed Tomography (HRCT) of the Chest, Clinical Score, and Pulmonary Function Measurements in Cystic Fibrosis (CF) Patients before and after Treatment for a Pulmonary Exacerbation. Pediatric Research, 1999, 45, 355A-355A.	1.1	1
143	8 Once a day theophylline (uniphyll) for treatment of patients with asthma (AS) and cystic fibrosis(CF). Journal of Allergy and Clinical Immunology, 1985, 75, 106.	1.5	0
144	282 A quantitative immunoenzymatic assay for grass pollen-specific IgG antibodies. Journal of Allergy and Clinical Immunology, 1985, 75, 175.	1.5	0

#	ARTICLE	IF	CITATIONS
145	486 Defective antibody-mediated opsonization of pseudomonas aeruginosa (PA) in cystic fibrosis (CF): An isotype-dependent defect?. Journal of Allergy and Clinical Immunology, 1988, 81, 289.	1.5	0
146	Vocal Cord Dysfunction Syndrome and "Steroid-Dependent" Asthmatics. Chest, 1995, 108, 1772-1773.	0.4	0
147	Clinical protocol: AAV-CFTR for the treatment of chronic sinusitis in CF patients.. Clinical Pharmacology and Therapeutics, 1996, 59, 174-174.	2.3	0
148	Study Of Sublingual Immunotherapy In Subjects With Dermatophagoides Farniae And Timothy Grass Allergy. Journal of Allergy and Clinical Immunology, 2009, 123, S126-S126.	1.5	0
149	Specific Induction Of CD203c Expression In Blood Basophils Discriminates Between CF patients With Aspergillus Colonization And Those With CF-ABPA. Journal of Allergy and Clinical Immunology, 2012, 129, AB139.	1.5	0